Hello Misiu: As always appreciate your voluminous postings and fearless attitude in questioning management either privately or in public setting.
Possibly lost in all the exciting news of potential partnerships, licensing agreements & TO financing to come was that Eli Lilly very recently had their TNBC CDK4/6 inhibitor drug Verzenio "flagged" by the Japanese health industry for safety concerns. Patients developed a serious lung disease and likely the cause of one death.
Lilly had high hopes for the drug and touted it as one its top oncology prospects. And in fact sales were pretty strong last quarter at $300 million I believe.
Novartis TNBC drug Kisqali has been a flop and the leader in the field by far is Pfizers Ibrance with worldwide sales of $1.1 billion last year - And as you know, this is dangerous nasty stuff patients are taking.
Obviously their is a huge need & market for a safe & effective treatment, let's get those 5 to 10 patients injected and prove Leronlimab can in fact be that savior.
Market Data 
Markets 
AI
